Cherry Hill: Daughter’s opioid death caused by ‘corporate greed’
As Seen In:
![nightline](https://richardhollstg.wpengine.com/wp-content/uploads/2022/06/nightline.png)
![newyorktimes](https://richardhollstg.wpengine.com/wp-content/uploads/2022/03/newyorktimes.png)
![inquirerfinal](https://richardhollstg.wpengine.com/wp-content/uploads/2022/06/inquirerfinal.png)
![the-wall-street-journal-logo-png-8-1](https://richardhollstg.wpengine.com/wp-content/uploads/2022/06/the-wall-street-journal-logo-png-8-1.png)
![finished-20-20](https://richardhollstg.wpengine.com/wp-content/uploads/2022/04/finished-20-20.png)
GET A FREE CONSULTATION
PRACTICE AREAS
RECENT RESULTS
![wrong-ful-death](https://richardhollstg.wpengine.com/wp-content/uploads/2022/05/wrong-ful-death.png)
![forklift](https://richardhollstg.wpengine.com/wp-content/uploads/2022/05/forklift.png)
![750-result](https://richardhollstg.wpengine.com/wp-content/uploads/2022/05/750-result.png)
U.S. Sen. Claire McCaskill (D., Mo.) took aim during a hearing Tuesday at marketing practices by the pharmaceutical industry generally and the behavior of one company in particular: Insys Therapeutics Inc., which made the powerful opioid believed to have played a role in the death of 32-year-old Sarah Fuller in Camden County last year.
Her mother, Deborah, described listening to an audio recording in which a drug company representative falsely said she was from Sarah’s doctor’s office and misled a pharmacy benefits manager into believing that Sarah had breakthrough cancer pain. That’s the only condition that Insys’ fast-acting fentanyl brand, Subsys, was approved to treat.
Read the full story on Philly.com